Holen Sie sich die Stockscreener-App
0.6416
4.57%
-0.0285
Handel nachbörslich:
.63
-0.0116
-1.81%
Schlusskurs vom Vortag:
$0.6701
Offen:
$0.6799
24-Stunden-Volumen:
780.61K
Relative Volume:
0.16
Marktkapitalisierung:
$25.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-0.2267
EPS:
-2.83
Netto-Cashflow:
$-101.06M
1W Leistung:
-1.08%
1M Leistung:
+35.34%
6M Leistung:
-74.62%
1J Leistung:
-62.16%
1-Tages-Spanne:
$0.6156
$0.6799
1-Wochen-Bereich:
$0.6156
$0.8264
52-Wochen-Spanne:
$0.4115
$4.2984
Athira Pharma Inc Stock (ATHA) Company Profile
Firmenname
Athira Pharma Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Vergleichen Sie ATHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ATHA | 0.6416 | 25.51M | 0 | -117.67M | -101.06M | -2.83 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
Athira Pharma's SWOT analysis: stock shifts focus after trial setback By Investing.com - Investing.com UK
Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline - MSN
Athira exploring strategic alternatives after Alzheimer’s failure - BioPharma Dive
Athira Pharma Reports Q3 2024 Financial Results - TipRanks
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - The Manila Times
What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register
Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360
US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St
Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN
Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan
Athira Pharma faces Nasdaq delisting over share price - Investing.com
A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News
A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News
A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily
Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily
Check out these key findings about Athira Pharma Inc (ATHA) - SETE News
Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News
Athira Pharma to lay off 70% of workforce - PharmaLive
Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily
Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex
Athira Pharma to Lay Off 70% of Workforce - BioSpace
After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule - Fierce Biotech
Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada
Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily
Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com
Athira Pharma downgraded to Neutral from Outperform at Mizuho - TipRanks
Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World
Taking the lead: Athira Pharma Inc (ATHA) - SETE News
Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals
Athira Pharma to Cut About 70% of Workforce - MarketWatch
Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks
Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire
Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex
Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News
Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily
Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex
AdPha urges HTA reform - Pharmacy Daily
Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today
Finanzdaten der Athira Pharma Inc-Aktie (ATHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Athira Pharma Inc-Aktie (ATHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gengos Andrew | CFO and Chief Business Officer |
Sep 05 '24 |
Sale |
0.57 |
1,272 |
720 |
97,532 |
| Lenington Rachel | COO and CDO |
Sep 05 '24 |
Sale |
0.57 |
2,525 |
1,429 |
20,870 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Sep 05 '24 |
Sale |
0.57 |
2,525 |
1,429 |
92,684 |
| Worthington Mark | GENERAL COUNSEL |
Sep 05 '24 |
Sale |
0.57 |
2,525 |
1,429 |
51,927 |
| Litton Mark James | President and CEO |
Sep 05 '24 |
Sale |
0.57 |
5,032 |
2,848 |
159,365 |
| Romano Kelly A | Director |
Jun 24 '24 |
Buy |
2.42 |
27,400 |
66,179 |
80,715 |
| Romano Kelly A | Director |
Jun 21 '24 |
Buy |
2.26 |
15,000 |
33,872 |
53,315 |
| Litton Mark James | Chief Executive Officer |
Jan 05 '24 |
Sale |
2.91 |
4,820 |
14,026 |
144,397 |
| Worthington Mark | General Counsel |
Jan 05 '24 |
Sale |
2.91 |
2,412 |
7,019 |
34,452 |
| Lenington Rachel | Chief Operating Officer |
Jan 05 '24 |
Sale |
2.91 |
2,412 |
7,019 |
13,395 |
4.27%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):